Pharmaceutical composition for gout

Details Pharmaceutical composition for gout Pharmaceutical composition for gout

2007-07-18

2010-11-16

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S551000, C514S556000

Reexamination Certificate

active

07834056

ABSTRACT:
A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.

REFERENCES:
patent: 2004/0242491 (2004-12-01), Chang
patent: 2006/0062859 (2006-03-01), Blum et al.
patent: 1762232 (2007-03-01), None
patent: 2006223224 (2006-08-01), None
patent: 2006347935 (2006-12-01), None
patent: WO9622774 (1996-08-01), None
patent: WO 00/27386 (2000-05-01), None
patent: WO0048636 (2000-08-01), None
patent: WO0122943 (2001-04-01), None
patent: WO0168534 (2001-09-01), None
patent: WO03068267 (2003-08-01), None
patent: WO2005023305 (2005-03-01), None
patent: WO2006054629 (2006-05-01), None
patent: WO2006087997 (2006-08-01), None
patent: WO2006105912 (2006-10-01), None
patent: WO2006105913 (2006-10-01), None
patent: WO2007059515 (2007-05-01), None
Lonza. L-carnitine vs. D-Carnitine. Published Online Mar. 2006, L-carnitine, p. 1.
Harris et al. American Academy of Family Physicians. Feb. 1999, pp. 1-16.
Dupond et al, “Exercise-induced enzymatic myopathies with normal creatinine kinase levels at rest”, Abstract in English, La Presse Medicale vol. 21, No. 21, pp. 974-978 (1992).
Fox, “Adenosine triphospate degradation in specific disease”, The J. of Lab. and Clinical Medicine vol. 106, No. 2, pp. 101-110 (1985).
Östman-Smith et al., “Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid”, Br. Heart J. 72, pp. 349-353 (1994).
Röschinger et al., “Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle”, Clinica Chimica Acta 298, pp. 55-68 (2000).
Verma “Persistent Hyperinsulinemic Hypoglycemia of Infancy”, Perinatology vol. 4, No. 1, pp. 43-49 (2002).
European Search Report for appl. No. 08714929.0-2123, mailed Mar. 17, 2010, 7 pgs.
Loots et al., “Acetyl-L-carnitine prevents total body hydroxyl free radical and uric acid production induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the rat”, Life Sciences 75, pp. 1243-1253 (2004).
Rauchova et al., “The effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats”, EU J. of Pharmacology 342 pp. 235-239 (1998).
Volek et al., “L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress”, Am. J. Physiol Endocrinol Metab 282, pp. E474-E482 (2002).

Affiliated with

Also associated with

Rating

Pharmaceutical composition for gout does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition for gout, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for gout will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4252443